(EBS) Emergent BioSolutions Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(EBS) Emergent BioSolutions Inc. Complete Analysis Pack
Unlock Strategic Clarity
This Emergent BioSolutions Inc. BCG Matrix is a company-specific strategy tool used to assess which products or business units fall into Stars, Cash Cows, Question Marks, or Dogs. This page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report instantly.
Stars
NARCAN 4 mg OTC naloxone
NARCAN 4 mg OTC naloxone is Emergent BioSolutions Inc.'s clearest Star: it has strong share in a growing U.S. overdose-prevention market, and over-the-counter access keeps the addressable base wide. The CDC reported 107,543 drug overdose deaths in 2023, so demand for naloxone stays high. Brand leadership matters here, and NARCAN remains the best-known OTC option.
Naloxone nasal spray franchise
The naloxone nasal spray franchise fits a Star: the 4 mg OTC format sits in a growing harm-reduction market, while pharmacy, public-health, and first-responder channels keep repeat demand high. U.S. overdose deaths were still above 80,000 in recent CDC 12-month data, so access stays urgent. Broad awareness and wide distribution help protect share.
Opioid overdose reversal market
U.S. opioid overdose deaths were about 80,391 in the 12 months ended Sep. 2024, so demand for reversal products stays high. Emergent BioSolutions’ NARCAN nasal spray posted $213.3 million in net sales in 2024, and the over-the-counter channel supports repeat purchases. This Star can scale fast because public programs and retail access keep volume recurring.
Consumer-facing rescue access
OTC NARCAN turned rescue access into a consumer channel, not just an institutional one. The FDA switch in March 2023 widened reach beyond first responders and hospitals, lifting unit demand and keeping the brand visible at retail. For Emergent BioSolutions Inc., this is one of the few spots with both growth and real brand pull.
- OTC expands the addressable market.
- Retail boosts unit demand and visibility.
- NARCAN is a rare brand-strength driver.
Public health naloxone channel
State, local, and community programs still push Naloxone at scale, with over 100,000 U.S. overdose deaths a year keeping demand high. For Emergent BioSolutions Inc., these channels support repeat use, broad access, and strong product rotation, so Public health naloxone looks like a Star, not a mature utility product.
- High-volume public channels sustain demand
- Overdose crisis keeps adoption elevated
- Repeat access supports franchise growth
- Star profile fits active public-health use
NARCAN Powers Emergent’s Growth as Demand Stays High
NARCAN is Emergent BioSolutions Inc.'s main Star: OTC access widened demand, while the U.S. overdose crisis kept need high. 2024 NARCAN net sales were $213.3 million, and CDC 12-month overdose deaths through Sep. 2024 were about 80,391, so this franchise still has strong growth and brand pull.
| Metric | Value |
|---|---|
| NARCAN net sales | $213.3 million, 2024 |
| U.S. overdose deaths | 80,391, 12 months ended Sep. 2024 |
| Key driver | OTC access |
What is included in the product
Detailed Word Document
Emergent BioSolutions BCG Matrix spots defense-biothreat cash cows, niche question marks, and weaker dogs to invest, hold, or divest.
Editable Excel File
One-page BCG Matrix for Emergent BioSolutions Inc. to pinpoint business units fast and simplify portfolio decisions
Reference Sources
Provides a credible source trail for Emergent BioSolutions Inc., helping users verify key claims fast and make better decisions.
Cash Cows
BioThrax 1 licensed anthrax vaccine
BioThrax is Emergent BioSolutions Inc.'s cash cow: it is the only FDA-licensed anthrax vaccine in the U.S. and sells into a mature federal preparedness market with few rivals. That keeps demand steady, pricing resilient, and promotion spend low. In a government-driven niche, BioThrax can keep generating cash even when growth is flat.
ACAM2000 1 of 2 U.S. smallpox vaccines
ACAM2000 is one of 2 U.S. smallpox vaccines, so it sits in a mature, low-growth stockpiling market. Its long-running U.S. government role supports steady procurement, and the product’s public-health use keeps demand durable even when volumes do not grow fast. That mix of high share and limited growth makes ACAM2000 a classic cash cow for Emergent BioSolutions Inc.
BAT 7-valent botulism antitoxin
BAT 7-valent botulism antitoxin is a classic Cash Cow for Emergent BioSolutions Inc.: it covers 7 serotypes, serves a narrow public-health niche, and depends on recurring U.S. strategic stockpile demand. The market is small and slow-growing, but preparedness buying keeps it relevant, so the asset can generate steady revenue with limited need for heavy growth spending. In BCG terms, it fits a mature, defense-linked product that supports cash flow more than expansion.
VIGIV smallpox vaccine complication therapy
VIGIV is a narrow biodefense product used only for vaccinia-related complications after smallpox vaccination, so it does not rely on broad market demand. In 2025, that kind of preparedness-driven need kept it low-growth but useful for cash flow, since government stockpiling matters more than repeat retail use.
- Rare, medical-use-only demand
- Driven by preparedness spending
- Low growth, steady cash generation
RSDL CBRN decontamination kits
RSDL decontamination kits fit Emergent BioSolutions Inc. cash-cow slot because they serve CBRN readiness and sell into steady institutional buying, not fast consumer demand. RSDL has been FDA-cleared for military and first-responder use since 2003, so the franchise is mature and keeps generating cash from repeat procurement.
- CBRN readiness drives recurring orders
- Mature product, low growth
- Institutional demand supports cash flow
Emergent BioSolutions’ Steady Cash Cows: Biodefense’s Reliable Revenue Engines
Emergent BioSolutions Inc.'s cash cows are mature biodefense assets: BioThrax, ACAM2000, BAT, VIGIV, and RSDL. They serve U.S. stockpile and preparedness demand, so growth is low but cash flow stays steady. In 2025, this mix still fit a classic BCG cash-cow profile: high share, weak growth, and recurring government orders.
| Product | Cash-cow cue |
|---|---|
| BioThrax | Only FDA-licensed anthrax vaccine |
| ACAM2000 | 1 of 2 U.S. smallpox vaccines |
| BAT | 7-serotype stockpile product |
| VIGIV | Niche post-vaccinia use |
| RSDL | Recurring CBRN readiness orders |
Preview the Actual Deliverable
Emergent BioSolutions Inc. Reference Sources
The Emergent BioSolutions Inc. BCG Matrix you’re previewing is the exact same document you’ll receive after purchase. No hidden changes, no demo content—just the full, ready-to-use report. You’ll get the same professionally formatted file for immediate download, editing, or presentation. What you see here is what you own.
Dogs
Vivotif oral typhoid vaccine
Vivotif is a travel vaccine in a narrow, low-growth niche, so it fits Emergent BioSolutions Inc.’s Dogs bucket. Typhoid still causes about 9 million to 14 million cases and 110,000 to 160,000 deaths a year, but the U.S. travel-vaccine market is small and crowded. With limited scale versus larger travel-health brands, Vivotif looks like a stable but weak-share asset.
Vaxchora single-dose oral cholera vaccine
Vaxchora is a single-dose oral vaccine for adults 18 to 64, but cholera prevention is still a narrow travel and outbreak use case. Emergent BioSolutions does not separately disclose Vaxchora sales, which signals a small commercial footprint and limited scale. With low volume and modest growth, it fits a weak BCG position, closer to a question mark than a star.
Trobigard dual auto-injector
Trobigard dual auto-injector is a niche CBRN countermeasure for nerve-agent emergency use, so demand depends on slow, procurement-led government buying. That kind of market is small and lumpy, which limits share upside and keeps returns tight. In Emergent BioSolutions Inc.'s mix, it fits a Dog: low growth, narrow use case, and limited scale.
COVID-HIG SARS-CoV-2 hyperimmune
COVID-HIG SARS-CoV-2 hyperimmune sits in the dog quadrant because the COVID-19 treatment market has shrunk hard since the 2020-2022 peak, and demand for passive immunotherapy is now thin. With most spending shifted to vaccination and only sporadic treatment use, the product has weak growth, weak pricing power, and limited pull in 2025-2026.
- Market demand has faded sharply.
- Commercial pull is now uncertain.
- Fits a low-growth dog profile.
Legacy CDMO manufacturing footprint
Emergent BioSolutions Inc.'s legacy CDMO manufacturing footprint fits Dog status: contract manufacturing is crowded, price-sensitive, and low-margin, while the unit has faced restructuring and utilization pressure. In 2025, the company kept cutting costs and narrowing its manufacturing base, which points to weak share in a tough market. That mix usually means limited growth and poor cash use.
- Low pricing power
- Weak utilization
- Restructuring drag
- Small share, low margin
Emergent’s Dogs: Small Markets, Weak Growth, Limited 2025–2026 Upside
Emergent BioSolutions Inc.’s Dogs are narrow, low-growth assets with weak scale: Vivotif, Vaxchora, Trobigard, COVID-HIG, and legacy CDMO. Typhoid still brings 9M-14M cases and 110k-160k deaths a year, but these brands sit in small, crowded markets with limited 2025-2026 commercial pull.
| Asset | Dog signal | Data |
|---|---|---|
| Vivotif | Low share | Small travel-vaccine niche |
| COVID-HIG | Weak demand | Treatment demand faded in 2025-2026 |
Question Marks
AV7909 anthrax vaccine candidate
AV7909 is a next-generation anthrax vaccine candidate with clear U.S. biodefense value, since anthrax preparedness stays a federal priority. Its commercial share is still 0 because it is not yet a scaled product. Emergent BioSolutions should keep funding development or secure a partner, because a 2-dose, easier-use profile could move it from Question Mark to Star if government demand converts.
AP003 multidose naloxone nasal spray
AP003 multidose naloxone nasal spray sits in a growing overdose-reversal market, with U.S. overdose deaths still at about 107,543 in the 12 months ended Sep. 2024. It can build on Emergent BioSolutions Inc.'s naloxone franchise, but it has no proven share or sales track record yet. That mix of high upside and unclear traction makes it a classic question mark.
AP007 sustained-release nalmefene injection
AP007 sustained-release nalmefene injection fits the question mark role: it targets opioid use disorder, a market with roughly 80,000 U.S. overdose deaths a year, but its sales are still unproven. For Emergent BioSolutions Inc., that means high need and high upside, but low current share and no clear commercial win yet. If uptake improves, AP007 could move toward a star; if not, it stays a costly bet.
CHIKV VLP chikungunya vaccine
Chikungunya is a high-need market: the WHO estimates about 5.6 billion people live in areas at risk, and outbreaks can spread fast. For Emergent BioSolutions Inc., CHIKV VLP is still a question mark because the market is emerging, but the asset has no commercial scale or proven revenue base yet.
That means upside is real, but so is execution risk. Until Emergent BioSolutions Inc. converts the program into late-stage data, regulatory progress, and sales, it stays in the question mark box.
- High unmet need, large at-risk population.
- Emerging market, no scale yet.
- High upside, high uncertainty.
UniFlu universal influenza vaccine
UniFlu is a Question Mark for Emergent BioSolutions Inc. because it targets a huge flu market, but it still has no sales or market share. Seasonal influenza causes up to 1 billion infections and 290,000-650,000 respiratory deaths a year, so a true universal vaccine could win a multi-billion-dollar market if efficacy and FDA/EMA milestones land.
For now, it needs heavy R&D spend and clinical proof before it can move toward Star status, so near-term value is optionality, not cash flow. That means high upside, but also high execution risk and a long path to commercialization.
- Huge market, zero current share
- Pipeline asset, not a revenue driver
- Needs funding, data, and approvals
- High upside if efficacy holds
Emergent’s Question Marks: Big Markets, Unproven Sales
Emergent BioSolutions Inc.'s Question Marks have big upside but no proven scale yet. AV7909, AP003, AP007, CHIKV VLP, and UniFlu all target urgent unmet needs, but each still lacks meaningful sales or market share. With U.S. overdose deaths at 107,543 in the 12 months ended Sep. 2024 and chikungunya risk near 5.6 billion people, success depends on trial wins, approvals, and adoption.
| Asset | Why it is a Question Mark | Key number |
|---|---|---|
| AV7909 | No scaled share yet | 0 sales base |
| AP003 | Unproven traction | 107,543 deaths |
| AP007 | High need, no win yet | 80,000 deaths |
| CHIKV VLP | Emerging market | 5.6 billion at risk |
| UniFlu | Huge market, no sales | 1 billion infections |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.